At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

Pfizer receives a tactical upgrade to Hold following its acquisition of Metsera, re-entering the obesity/GLP-1 market with promising clinical assets. The Metsera deal offers PFE strategic optionality ...

As its lead candidate advances into a late-stage trial for pulmonary arterial hypertension (PAH), Inhibikase Therapeutics has picked up a commercial leader with plenty of experience in the PAH space.

ZURICH (MarketWatch) -- Swiss biotechnology company Cytos Biotechnology Ltd (CYTN.EB) said Monday Pfizer Inc. PFE has taken commercial licenses for specified vaccines based on Cytos' immunodrug ...

Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that increasingly cares more about income than growth. The company's dividend has ...